Related Experiment Video
Updated: Aug 15, 2026
Induction and Testing of Hypoxia in Cell Culture
Published on: August 12, 2011
Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia
Louisa M Brown1, Rachel L Cowen, Camille Debray
1Experimental Oncology, School of Pharmacy and Pharmaceutical Sciences, University of Manchester, UK.
Abstract:
The resistance of hypoxic cells to conventional chemotherapy is well documented. Using both adenovirus-mediated gene delivery and small molecules targeting hypoxia-inducible factor-1 (HIF-1), we evaluated the impact of HIF-1 inhibition on the sensitivity of hypoxic tumor cells to etoposide. The genetic therapy exploited a truncated HIF-1alpha protein that acts as a dominant-negative HIF-1alpha (HIF-1alpha-no-TAD). Its functionality was validated in six human tumor cell lines using HIF-1 reporter assays. An EGFP-fused protein demonstrated that the dominant-negative HIF-1alpha was nucleus-localized and constitutively expressed irrespective of oxygen tension. The small molecules studied were quinocarmycin monocitrate (KW2152), its analog 7-cyanoquinocarcinol (DX-52-1), and topotecan. DX-52-1 and topotecan have been previously established as HIF-1 inhibitors. HT1080 and HCT116 cells were treated with either AdHIF-1alpha-no-TAD or nontoxic concentrations (0.1 microM;
Insights
Hypoxic tumor cells resist chemotherapy, but inhibiting hypoxia-inducible factor-1 (HIF-1) with gene therapy or small molecules can restore sensitivity to etoposide. This approach overcomes treatment resistance in hypoxic cancer cells.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Hypoxic tumor cells exhibit resistance to conventional chemotherapy, a significant challenge in cancer treatment.
- Hypoxia-inducible factor-1 (HIF-1) plays a crucial role in mediating this resistance.
- Targeting HIF-1 offers a potential strategy to overcome chemoresistance in hypoxic tumors.
Purpose of the Study:
- To evaluate the impact of HIF-1 inhibition on the sensitivity of hypoxic tumor cells to etoposide.
- To assess the efficacy of both adenovirus-mediated gene delivery and small molecule inhibitors of HIF-1.
- To investigate the role of HIF-1 in regulating proapoptotic proteins under hypoxic conditions.
Main Methods:
- Adenovirus-mediated delivery of a dominant-negative HIF-1alpha (HIF-1alpha-no-TAD) and treatment with HIF-1 inhibitors (KW2152, DX-52-1).
- Exposure of human tumor cell lines (HT1080, HCT116) to etoposide under normoxic and anoxic conditions.
- Validation of HIF-1 inhibition using reporter assays and assessment of etoposide IC(50) values.
Main Results:
- Etoposide displayed significantly higher IC(50) values in anoxia compared to air, indicating chemoresistance.
- Small molecules KW2152 and DX-52-1 partially restored etoposide sensitivity in HT1080 cells, with KW2152 also effective in HCT116 cells.
- AdHIF-1alpha-no-TAD completely abolished anoxic etoposide resistance in both cell lines and inhibited HIF-1-mediated Bid downregulation.
Conclusions:
- Inhibition of HIF-1, particularly via gene therapy with AdHIF-1alpha-no-TAD, effectively sensitizes hypoxic tumor cells to etoposide.
- HIF-1 plays a key role in chemoresistance by downregulating proapoptotic proteins like Bid under hypoxia.
- Targeting HIF-1 in combination with chemotherapy presents a promising therapeutic strategy for overcoming treatment failure in hypoxic tumors.
Related Concept Videos
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:56Treatment Resistant Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:24Regulation of Angiogenesis and Blood Supply